Greenridge Exploration Inc. ('Greenridge” or the 'Company”) (CSE: GXP | FRA: HW3 | OTCQB: GXPLF), is pleased to announce it has commenced a helicopter-borne time-domain electromagnetic ('HTDEM”) ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par ...

Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in ...

LAWRENCEVILLE, N.J. - IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company with a market capitalization of $24.07 million, presented new translational data from its Phase 2 OVATION 2 ...

Furthermore, IMUNON’s Phase 2 OVATION 2 Study of IMNN-001 for ovarian cancer showed significant improvements in survival rates, indicating promise for future treatment options.

IMUNON’s announcement is based on a press release statement from the clinical-stage biotechnology company. For deeper insights into IMUNON’s financial health and growth prospects, InvestingPro ...

Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology ...

Wall Street Zen upgraded shares of Imunon (NASDAQ:IMNN – Free Report) to a sell rating in a research note released on Friday morning. IMNN has been the topic of several other reports. D Boral ...

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the“safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized ...

--IMUNON, Inc., a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced positive data from the Company’ s Phase 2 OVATION 2 Study showing that ...